Literature DB >> 22161776

Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

Katherine J O'Malley1, Gabrielle Langmann, Junkui Ai, Raquel Ramos-Garcia, Robert L Vessella, Zhou Wang.   

Abstract

BACKGROUND: Advanced prostate cancer is currently treated with androgen deprivation therapy (ADT). ADT initially results in tumor regression; however, all patients eventually relapse with castration-resistant prostate cancer. New approaches to delay the progression of prostate cancer to castration resistance are in desperate need. This study addresses whether targeting Heat shock protein 90 (HSP90) regulation of androgen receptor (AR) can inhibit prostate cancer progression to castration resistance.
METHODS: The HSP90 inhibitor 17-AAG was injected intraperitoneally into nude mice bearing LuCaP35 xenograft tumors to determine the effect of HSP90 inhibition on prostate cancer progression to castration resistance and host survival.
RESULTS: Administration of 17-AAG maintained androgen-sensitivity, delayed the progression of LuCaP35 xenograft tumors to castration resistance, and prolonged the survival of host. In addition, 17-AAG prevented nuclear localization of endogenous AR in LuCaP35 xenograft tumors in castrated nude mice.
CONCLUSIONS: Targeting Hsp90 or the mechanism by which HSP90 regulates androgen-independent AR nuclear localization and activation may lead to new approaches to prevent and/or treat castration-resistant prostate cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161776      PMCID: PMC3319476          DOI: 10.1002/pros.22458

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

1.  Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Authors:  P N Münster; M Srethapakdi; M M Moasser; N Rosen
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 2.  Molecular chaperones and subcellular trafficking of steroid receptors.

Authors:  D B DeFranco; C Ramakrishnan; Y Tang
Journal:  J Steroid Biochem Mol Biol       Date:  1998-04       Impact factor: 4.292

Review 3.  Steroid receptor interactions with heat shock protein and immunophilin chaperones.

Authors:  W B Pratt; D O Toft
Journal:  Endocr Rev       Date:  1997-06       Impact factor: 19.871

4.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Authors:  C W Gregory; R T Johnson; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor.

Authors:  V Georget; J M Lobaccaro; B Terouanne; P Mangeat; J C Nicolas; C Sultan
Journal:  Mol Cell Endocrinol       Date:  1997-04-25       Impact factor: 4.102

6.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Authors:  David B Solit; Fuzhong F Zheng; Maria Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

Review 7.  The androgen receptor: an overview.

Authors:  Z X Zhou; C I Wong; M Sar; E M Wilson
Journal:  Recent Prog Horm Res       Date:  1994

Review 8.  Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction.

Authors:  A K Roy; R K Tyagi; C S Song; Y Lavrovsky; S C Ahn; T S Oh; B Chatterjee
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

9.  The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Authors:  C P Webb; C D Hose; S Koochekpour; M Jeffers; M Oskarsson; E Sausville; A Monks; G F Vande Woude
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

10.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.

Authors:  Ofelia L Zegarra-Moro; Lucy J Schmidt; Haojie Huang; Donald J Tindall
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

View more
  15 in total

Review 1.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

2.  Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.

Authors:  Raquel Ramos Garcia; Khalid Z Masoodi; Laura E Pascal; Joel B Nelson; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

Review 3.  Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

Authors:  Arun A Azad; Amina Zoubeidi; Martin E Gleave; Kim N Chi
Journal:  Nat Rev Urol       Date:  2014-12-16       Impact factor: 14.432

4.  5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

Authors:  Khalid Z Masoodi; Raquel Ramos Garcia; Laura E Pascal; Yujuan Wang; Hei M Ma; Katherine O'Malley; Kurtis Eisermann; Daniel H Shevrin; Holly M Nguyen; Robert L Vessella; Joel B Nelson; Rahul A Parikh; Zhou Wang
Journal:  Endocrinology       Date:  2013-05-13       Impact factor: 4.736

5.  The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.

Authors:  Javid A Dar; Khalid Z Masoodi; Kurtis Eisermann; Sudhir Isharwal; Junkui Ai; Laura E Pascal; Joel B Nelson; Zhou Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2014-03-22       Impact factor: 4.292

6.  A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Authors:  Manish K Thakur; Lance K Heilbrun; Shijie Sheng; Mark Stein; Glenn Liu; Emmanuel S Antonarakis; Ulka Vaishampayan; Sijana H Dzinic; Xiaohua Li; Stacy Freeman; Daryn Smith; Elisabeth I Heath
Journal:  Invest New Drugs       Date:  2015-11-18       Impact factor: 3.850

7.  Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

Authors:  Roberta Ferraldeschi; Jonathan Welti; Marissa V Powers; Wei Yuan; Tomoko Smyth; George Seed; Ruth Riisnaes; Somaieh Hedayat; Hannah Wang; Mateus Crespo; Daniel Nava Rodrigues; Ines Figueiredo; Susana Miranda; Suzanne Carreira; John F Lyons; Swee Sharp; Stephen R Plymate; Gerhardt Attard; Nicola Wallis; Paul Workman; Johann S de Bono
Journal:  Cancer Res       Date:  2016-05-01       Impact factor: 12.701

8.  Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

Authors:  Suqin He; Chaohua Zhang; Ayesha A Shafi; Manuel Sequeira; Jaime Acquaviva; Julie C Friedland; Jim Sang; Donald L Smith; Nancy L Weigel; Yumiko Wada; David A Proia
Journal:  Int J Oncol       Date:  2012-11-14       Impact factor: 5.650

9.  Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Authors:  Joanna L Gillis; Luke A Selth; Margaret M Centenera; Scott L Townley; Shihua Sun; Stephen R Plymate; Wayne D Tilley; Lisa M Butler
Journal:  Oncotarget       Date:  2013-05

10.  Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Authors:  ShengYu Ku; Elena Lasorsa; Remi Adelaiye; Swathi Ramakrishnan; Leigh Ellis; Roberto Pili
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.